CYTK
Cytokinetics, Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -11.8% ·
share flow -4.9% ·
net new positions -13.3%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 11.48K | $711,878 | n/a | n/a |
| Q2 2026 | 126 | +7 | 95.69M | $8.15B | +10 | −4 |
| Q1 2026 | 123 | +1 | 87.96M | $5.79B | +8 | −8 |
| Q4 2025 | 121 | -1 | 92.45M | $5.87B | +2 | −2 |
| Q3 2025 | 19 | +2 | 69.14M | $3.80B | +2 | −1 |
| Q2 2025 | 15 | -2 | 62.06M | $2.05B | n/a | −2 |
| Q1 2025 | 14 | +1 | 26.36M | $1.06B | +1 | n/a |
| Q4 2024 | 13 | -1 | 25.19M | $1.18B | n/a | −1 |
| Q3 2024 | 13 | +2 | 19.21M | $1.01B | +2 | n/a |
| Q2 2024 | 11 | n/a | 17.42M | $943.61M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 15.68M | n/a | $518.00M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (passive) | 11.98M | n/a | $395.95M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | Fidelity (FMR) ✦ | 11.27M | n/a | $372.28M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 4 | Wellington Management ✦ | 7.83M | -2.0% | $258.63M | 0.0% | ▼ Trim | 5 | SEC ↗ ×8 |
| 5 | State Street Global Advisors ✦ (passive) | 6.37M | +4.7% | $210.56M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 2.99M | +1.9% | $98.95M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | T. Rowe Price ✦ | 1.87M | -6.4% | $61.65M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Citadel Advisors ✦ | 1.30M | +12.9% | $42.91M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | Norges Bank ✦ (passive) | 1.18M | +0.6% | $39.12M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | Fisher Asset Management ✦ | 733.68K | -7.5% | $24.24M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | Millennium Management ✦ | 458.68K | +59.3% | $15.15M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 347.74K | +1639.2% | $11.49M | 0.0% | ▲ Add | 5 | SEC ↗ ×3 |
| 13 | Marshall Wace ✦ | 21.23K | -99.0% | $701,274 | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 14 | D. E. Shaw & Co. ✦ | 19.08K | +43.5% | $630,535 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 10.17K | -91.6% | $335,918 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $69.25M | was 0.2% |
| Two Sigma Investments | $1.77M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 437 holders, 145.17M shares, $8.22B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.50K sh · $224,035
Officer, Director · 7.50K sh · $471,600
Officer · 3.50K sh · $214,830
Officer, Director · 7.50K sh · $490,950
Officer · 3.50K sh · $239,015
Officer, Director · 97.93K sh · $6.79M
Director · 1.00K sh · $72,130
Officer, Director · 7.50K sh · $550,800
Director · 1.00K sh · $74,660
Officer · 3.50K sh · $264,110
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology